These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 400808)

  • 21. Clofazimine therapy of lepromatous leprosy caused by dapsone-resistant mycobacterium leprae.
    Levy L; Shepard CC; Fasal P
    Am J Trop Med Hyg; 1972 May; 21(3):315-21. PubMed ID: 4554496
    [No Abstract]   [Full Text] [Related]  

  • 22. Secondary dapsone-resistant leprosy in Shanghai Municipality.
    Ji BH; Chen JK; Zhang JL; Hou YH; Ni GX; Zhang RB
    Lepr Rev; 1983 Sep; 54(3):197-202. PubMed ID: 6355724
    [No Abstract]   [Full Text] [Related]  

  • 23. Activity of ofloxacin against Mycobacterium leprae in the mouse.
    Grosset JH; Guelpa-Lauras CC; Perani EG; Beoletto C
    Int J Lepr Other Mycobact Dis; 1988 Jun; 56(2):259-64. PubMed ID: 3045223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The sensitivity to Dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1969 Mar; 18(2):258-63. PubMed ID: 4888029
    [No Abstract]   [Full Text] [Related]  

  • 25. Clarithromycin is bactericidal against strains of Mycobacterium leprae resistant and susceptible to dapsone and rifampin.
    Walker LL; Van Landingham RM; Shinnick TM
    Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):59-65. PubMed ID: 8326182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of secondary dapsone resistance in Nepal.
    Samuel NM; Samuel S; Loudon J; Neupani K; Adiga RB
    Indian J Lepr; 1984; 56(4):823-7. PubMed ID: 6398344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical and paraclinical aspects of secondary drug resistance to 4-4' diaminodiphenylsulfone in a population of leprosy patients in Bamako, Republic of Mali].
    Baquillon G; Ferracci C; Diallo J; Saint-Andreé P; Pattyn SR
    Acta Leprol; 1981; 85():40-52. PubMed ID: 6805234
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
    Dhople AM; Lamoureux LC; Gardner GD
    Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A statistical analysis of two chemotherapy trials in lepromatous leprosy. I. The response to therapy as measured by inoculation of mice.
    Am J Trop Med Hyg; 1978 Sep; 27(5):1005-14. PubMed ID: 362950
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary dapsone resistance in leprosy.
    Vaishnavi C; Ganguly NK; Kumar B; Kaur S; Chakravarti RN
    Indian J Lepr; 1985; 57(3):507-13. PubMed ID: 3913705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in the study of the leprosy bacillus.
    Rees RJ
    Sci Basis Med Annu Rev; 1969; ():320-35. PubMed ID: 4917843
    [No Abstract]   [Full Text] [Related]  

  • 32. Dormancy, drug resistance or dependency; some thoughts to ponder.
    Shetty VP; Mistry NF; Uplekar MW; Antia NH; Pai VV; Ganapati R
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):455-7. PubMed ID: 9030116
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies.
    Rees RJ; Waters MF; Pearson JM; Helmy HS; Laing AB
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):159-69. PubMed ID: 776852
    [No Abstract]   [Full Text] [Related]  

  • 34. Dapsone-resistant leprosy in Jakarta: a preliminary report.
    Utji R; Kosasih A; Santoso AU
    Lepr Rev; 1983 Sep; 54(3):193-5. PubMed ID: 6355723
    [No Abstract]   [Full Text] [Related]  

  • 35. [Action of desoxyfructo-serotonin on Mycobacterium leprae. Results of inoculation of human biopsy specimens in the mouse after a year of treatment].
    Ferracci C; Baquillon G; Pattyn SR
    Acta Leprol; 1983; 1(4):233-5. PubMed ID: 6377799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 37. Hydnocarpus oil as an antileprotic agent in footpad technique.
    Desai AC; Bhide MB
    Lepr India; 1977 Jul; 49(3):360-3. PubMed ID: 338984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenosine triphosphate content of Mycobacterium leprae from leprosy patients.
    Dhople AM
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):183-8. PubMed ID: 6373626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
    Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
    Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on dapsone-resistant Mycobacterium leprae in leprosy patients of Gudiyatham Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 2. A progress report.
    Almeida JG; Christian M; Chacko CJ; Taylor PM; Fritschi EP
    Lepr Rev; 1983 Sep; 54(3):185-91. PubMed ID: 6355722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.